Emergent BioSolutions Inc (NYSE:EBS) Share Price

Company Profile

Business description
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Contact
300 Professional Drive
GaithersburgMD20879
USA
T: +1 240 631-3200
E: [email protected]
https://www.emergentbiosolutions.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
900

Recommended

Real estate share remains cheap despite losing airport legal battle.

Yingqi Tan, CFA | 12 June 2026

The ChatGPT maker joined Anthropic in filing a confidential S-1 with the SEC, teeing up a future IPO.

Jacob Robbins | 11 June 2026

We see a solid business case for a merger, but not without hurdles, including Tesla shareholders’ concern about SpaceX’s valuation.

Seth Goldstein, CFA | 11 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,006.10	29.10	0.32%
CAC 40	8,347.67	146.88	1.79%
DAX 40	24,585.35	375.64	1.55%
Dow JONES (US)	50,848.75	929.97	1.86%
FTSE 100	10,416.73	112.85	1.10%
HKSE	24,718.10	468.81	1.93%
NASDAQ	25,809.66	640.16	2.54%
Nikkei 225	66,020.04	1,802.77	2.81%
NZX 50 Index	13,393.87	191.71	1.45%
S&P 500	7,394.30	127.31	1.75%
S&P/ASX 200	8,804.00	30.50	0.35%
SSE Composite Index	4,031.51	44.50	1.12%